Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $8.4 million.

  • Axsome Therapeutics' Gains from Investment Securities fell 10.25% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 10.25%. This contributed to the annual value of $8.4 million for FY2024, which is 0.27% down from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Gains from Investment Securities is $8.4 million, which was down 0.27% from $8.5 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Gains from Investment Securities high stood at $8.5 million for FY2023, and its period low was $176,000 during FY2021.
  • For the 3-year period, Axsome Therapeutics' Gains from Investment Securities averaged around $7.8 million, with its median value being $8.4 million (2024).
  • As far as peak fluctuations go, Axsome Therapeutics' Gains from Investment Securities skyrocketed by 6,414.09% in 2020, and later slumped by 90.19% in 2021.
  • Over the past 5 years, Axsome Therapeutics' Gains from Investment Securities (Yearly) stood at $1.8 million in 2020, then crashed by 90.19% to $176,000 in 2021, then soared by 3,660.07% to $6.6 million in 2022, then climbed by 27.87% to $8.5 million in 2023, then fell by 0.27% to $8.4 million in 2024.